Industry
Biotechnology
Topic
IPOs
People
Find news about people
Organizations
Find news about organizations
Alumni
Find news on alumni of any org
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
IPOs in Biotechnology
... SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for ...
... WOBURN, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) today announced the pricing of an underwritten public offering of ...
... SAN DIEGO, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed ...
... Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for ...
... bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene ...
... SOUTH SAN FRANCISCO, CA --(Marketwired - December 11, 2017) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN) ("VistaGen" or the "Company"), a clinical-stage biopharmaceutical company focused on ...
... SOUTH SAN FRANCISCO, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the pricing of its initial public offering of ...
... members with timely information, WallStEquities.com has issued free tailored Stock Review on PLX, XXII, CRMD, and IBIO which is a click away athttp://www.wallstequities.com/registration. Featured on ...
... WALTHAM, Mass. and VIENNA, Austria, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to ...
... launches in history. Demand for SPINRAZA remains strong in the U.S., with Biogen reporting a 75% increase in the number of patients on therapy in ...
... RAMSEY, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and ...
... to list on the NYSE as "BXG." [ts_bullet_primary] Fireman B.V . or InflaRx , a Jena, Germany,-based pharmaceutical company developing treatments for inflammatory diseases, raised ...
... Germany-based InflaRx, a developer of new therapeutics in the “terminal complement space,” has raised ...
... company plans to list on the NYSE. [ts_bullet_primary] Fireman B.V . or InflaRx , a Jena, Germany,-based pharmaceutical company developing treatments for inflammatory diseases, said ...
... deal. The company plans to list on the Nasdaq as "MDB." [ts_bullet_primary] Rhythm Pharmaceuticals , a biotech developing obesity treatments, raised $120 million in an ...
... deal. The company plans to list on the Nasdaq as "MBIN." [ts_bullet_primary] Rhythm Pharmaceuticals, a biotech developing obesity treatments, says it plans to raise $100 ...
... hard to hire new executives. Inside the Equifax hack. VENTURE DEALS [ts_bullet_primary] Sonendo, Inc . , a Laguna Hills, Calif.-based dental technology company, raised $50 ...
... Rhythm Pharmaceuticals, a 2016 Fierce 15 winner, is looking to get off a ...
... Science Platform - CAMBRIDGE, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development ...
... stocks: Zoetis Inc. (NYSE: ZTS), Sophiris Bio Inc. (NASDAQ: SPHS), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Neurocrine Biosciences Inc. (NASDAQ: NBIX) to see how they ...
... Kadmon Holdings, Inc. (NYSE:KDMN), a fully integrated biopharmaceutical company engaged in the discovery, development ...
... to purchase additional stockAt the end of the second quarter of 2016, Selecta had cash, cash equivalents, investments and restricted cash of $85.3 million WATERTOWN, ...
... Kadmon Holdings, Inc. today announced the pricing of its initial public offering of 6,250,000 ...
... UTRECHT, The Netherlands, July 12, 2016 (GLOBE NEWSWIRE) -- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced ...
... Watertown, Massachusetts-based Selecta Biosciences, a clinical stage biotech company, has raised $70 million for its ...
Want to see the full history on IPOs in Biotechnology? Upgrade to RelSci Pro now!
Start My Free Trial